Showing 2811-2820 of 8921 results for "".
Noah Worcester 2024: Dr. Jogi on Hair Loss
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-jogi-hair-loss/24590/Joel L. Cohen, MD, FAAD, interviews Reena Jogi, MD about her lecture on hair loss and platelet-rich plasma at the 2024 Noah Worcester Dermatological Society meeting.DermwireTV Extra: More than Skin Deep
https://practicaldermatology.com/series/dermwire-tv/more-than-skin-deep/20153/Julie Block, President & CEO at the National Eczema Association, discusses the toll that a child's eczema can take on the whole family. Visit understandad.com to learn more and to access the new Blue’s Clues & You! Storybook.DERM2020 Content Recap: Linda Stein Gold, MD
https://practicaldermatology.com/conferences/dermatology-education-foundation-derm-2020/derm2020-content-recap-linda-stein-gold-md/19845/DERM2020 Faculty Linda Stein Gold, MD discusses what’s new in acne from her presentation during DERM2020.Dupixent, Juvéderm Vollure XC, Bavencio Approvals
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-dupixent-juv-derm-vollure-xc-bavencio-approvals/18698/The FDA has approved Regeneron's injectable Dupixent (dupilumab) to treat adults with moderate-to-severe eczema. It will be marketed by Regeneron and Sanofi Genzyme in the US. Allergan's Juvéderm Vollure XC has received FDA approval based on a pivotal clinical trial in which 59 percent of subjects sUpdates on NMSC, Zika, Aesthetics from Summer AAD Meeting
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-updates-on-nmsc-zika-aesthetics-from-summer-aad-meeting/18735/From the dermatologist's role in preparing for Zika to the latest advancements in aesthetics, the Summer meeting of the American Academy of Dermatology in Boston offered fresh insights for practitioners. Get updates on AK Management, the Zika risk, dermatologic care for nursing mothers, fillers, andTelemedicine and Access, Inappropriate Antibiotics, Industry Growth
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-telemedicine-and-access-inappropriate-antibiotics-industry-growth/18602/New research published online in JAMA Dermatology suggests that teledermatology improves access to care. Experts predict continued growth of telemedicine in dermatology. New estimates suggest that 30% of antibiotic prescriptions may be inappropriate. Dermatologists warn against antibiotic misuse andICD-10: When the Rubber Meets the Road
https://practicaldermatology.com/topics/practice-management/icd-10-when-the-rubber-meets-the-road/18632/When plans to move to ICD-10 were first announced, providers expressed concerns about potential logistical concerns with the new coding system. However, now that the new system is in regular use, Leon Kircik, MD said health claim denial rates have been lower than expected and the transition has beenAnalyzing Safety Data From Level Up
https://practicaldermatology.com/series/the-practical-dermatology-podcast/analyzing-safety-data-from-level-up/33944/The latest news and updates, plus Matthew Zirwas, MD, FAAD, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss the importance of the Week 16 safety data from the Level Up study on upadacitinib. Silverberg JI, Bunick CG, et al. Efficacy and safety of upadacitinib versuNoah Worcester 2024: Dr. Webster on Isotretinoin
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-webster-isotretinoin/24581/Guy Webster, MD, PhD, FAAD, summarizes his lecture on new developments in isotretinoin at the 2024 Noah Worcester Dermatological Society meeting.Why Assessing Vitiligo Activity is Critical for Limiting Spread
https://practicaldermatology.com/conferences/maui-derm-2024/why-assessing-vitiligo-activity-is-critical-for-limiting-spread/20248/Chief Medical Editor Neal Bhatia, MD talks with “Mr. Vitiligo Himself,” John E. Harris, MD, PhD about the importance of determining whether vitiligo patients are active or stable in order to “shut off” spreading as soon as possible.